Engineering personalized
neoantigen vaccine
revolution

nanosferic structure
Enabling precision oncology.
Unprecedented neoantigen concentration.
Targeting T cell and B cell immune response.
Off-the-shelf scaffold.
Melanoma as a prime target.
Neoantigen vaccines

nanoSFERICTM technology combines advances in protein science, data science, and manufacturing to make personalized cancer vaccines more accessible. It also enables doctors and researchers to test and refine treatments more rapidly than ever before. Ultimately, nanoSFERICTM aims to bring powerful, individualized immunotherapy to more patients worldwide.

lab
Technology

We developed nanoSFERIC, a proprietary self-assembling protein nanoparticle platform with superior immunogenicity

The assembled nanoSFERIC particles form immunogenic rings with repeating target epitopes in eukaryotic and prokaryotic expression systems.

The planar presentation of repeating epitopes to B cells augments cross-linking of the immune receptors, boosting cell activation and specific antibody production.

Platform diversity

Infectious disease

Oncology

Veterinary

Antibacterial

Immunomodulatory

Diagnostics

Pipeline
pipeline
Services

R&D and manufacturing services

At Sferogen, we have developed a tailored manufacturing pipeline to achieve clinical-grade vaccine purity, paving the way to the clinic.

 

We offer platform independent development (recombinant, mRNA, etc).

Publications    
The team

In our team, experts from diverse fields have joined forces to accelerate the journey from discovery to clinic.

Urban BEZELJAK

Urban BEZELJAK

PhD, CEO and
Chief R&D

At Sferogen, Urban is the leading inventor of the proprietary nanoSFERIC vaccine platform, leading the research and design of this versatile technology. Urban is a molecular biology and biochemistry expert with experience in mammalian and insect cell culture expression technology. He earned his Master's degree in biochemistry at the University of Ljubljana (Slovenia) and holds a PhD from the Institute of Science and Technology Austria.
Alexander JERMAN

Alexander JERMAN

MD, CMO,
nephrologist

At Sferogen, Alexander is working closely with the advisory committee to identify new targets, plan preclinical trials and pave the way for the first-in human trials. Alexander is a scientist-physician with experience in immunology, nephrology and blood-purification. He holds an M.D. with honors from the University of Ljubljana and is a certified nephrologist.
Uroš FERJANČIČ

Uroš FERJANČIČ

MSc, COO,
tech transfer specialist

As chief operating officer at Sferogen, Uroš is responsible for planning and implementing of the company's daily operational functions, including management of purchasing, accounting (ERP, IT, IP), intellectual property, infrastructure, marketing, business planning, and branding. With over two decades of experience in sales, marketing, and manufacturing processes, Uroš brings a specialized interest in technology transfer to the role.
Matjaž PETERKA

Matjaž PETERKA

PhD,
Business Development

Matjaž is co-founder of Sferogen, guiding the long-term research strategy and overseeing business development activities. With over 20 years of leadership experience in the biotech industry, Matjaž has a proven track record in multifaceted roles, including extensive expertise in the manufacturing of viral vaccines, and bioprocess control.
Our story

Sferogen was established in 2022 as a spin-off company from COBIK, a research and development organization in the field of biotechnology.

eVLP

We developed an enveloped virus-like particle (eVLP) lead COVID-19 vaccine candidate, nSfCoVac, using a high-throughput insect cell line. This vaccine consists of three main SARS-CoV-2 structural proteins. We introduced innovative purification steps to yield pure virus-like particles with the desired morphology. Preclinical studies on a mouse model proved the immunogenicity on par with approved vaccines.

nanoSFERIC

We developed an innovative recombinant nanoSFERIC platform that has a number of key features, including a modular design, fast antigen switching, and scalable production. Our lead vaccine candidate demonstrated a strong immune response after single dose in a preclinical model antibody response.

Contact

Work with us

Our aim is to turn most innovative ideas into reality. That is why we are constantly challenging concepts, seeking new ideas and looking for bold, pioneering partners.

We believe that next decade will wittnes paradigm shifts in our understanding of immune system and system biology. This, in concert with current pace of innovation in biotechnology will enable the design of novel, better and safer vaccines for global health. On the other side, our ability to recognize and tackle personalized traits in oncology will exponentially expand the area of personalized medicine. This will result in bringing together the multiple layers of current knowledge and expertise into a One Health.

We are looking for innovative talents in research, biotechnology, clinical medicine and regulation to help us achieve our abitious goals.

Writte or call us on:

+386(0)40 54 84 64
info@sferogen.com